Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Urelumab (BMS-663513) in patients with advanced/metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma reports s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• Urelumab (urelumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED